Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Medtronic
McKinsey
Johnson and Johnson
Dow

Last Updated: March 26, 2023

TRIESENCE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


When do Triesence patents expire, and when can generic versions of Triesence launch?

Triesence is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug.

This drug has twenty-five patent family members in twenty-one countries.

The generic ingredient in TRIESENCE is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Sixty-nine suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.

Summary for TRIESENCE
Drug patent expirations by year for TRIESENCE
Drug Prices for TRIESENCE

See drug prices for TRIESENCE

US Patents and Regulatory Information for TRIESENCE

TRIESENCE is protected by three US patents.

Patents protecting TRIESENCE

Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: VISUALIZATION DURING VITRECTOMY PROCEDURES

Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF OPHTHALMIC DISORDERS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis TRIESENCE triamcinolone acetonide INJECTABLE;INTRAVITREAL 022048-001 Nov 29, 2007 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Novartis TRIESENCE triamcinolone acetonide INJECTABLE;INTRAVITREAL 022048-001 Nov 29, 2007 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for TRIESENCE

See the table below for patents covering TRIESENCE around the world.

Country Patent Number Title Estimated Expiration
Mexico 2010009974 SUSPENSIONES DE ACETONIDA DE TRIAMCINOLONA DE BAJA VISCOSIDAD, ALTAMENTE FLOCULADAS PARA INYECCION INTRAVITREA. (LOW VISCOSITY, HIGHLY FLOCCULATED TRIAMCINOLONE ACETONIDE SUSPENSIONS FOR INTRAVITREAL INJECTION.) See Plans and Pricing
Japan 2011513492 See Plans and Pricing
Argentina 070824 SUSPENSIONES PARA INYECCION INTRAVITREA DE TRIAMCINOLONA ACETONIDO DE BAJA VISCOSIDAD, ALTAMENTE FLOCULADAS See Plans and Pricing
Taiwan 200940071 Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection See Plans and Pricing
European Patent Office 2262506 SUSPENSIONS D ACÉTONIDE DE TRIAMCINOLONE TRÈS FLOCULÉES ET DE FAIBLE VISCOSITÉ POUR INJECTION INTRAVITRÉENNE (LOW VISCOSITY, HIGHLY FLOCCULATED TRIAMCINOLONE ACETONIDE SUSPENSIONS FOR INTRAVITREAL INJECTION) See Plans and Pricing
Uruguay 31699 SUSPENSIONES DE ACETONIDO DE TRIAMCINOLONA DE BAJA VISCOSIDAD Y ELEVADA FLOCULACION PARA INYECCION INTRAVITREA See Plans and Pricing
World Intellectual Property Organization (WIPO) 2009114521 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Colorcon
Merck
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.